Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Brainstorm Cell Therapeutics stock

Learn how to easily invest in Brainstorm Cell Therapeutics stock.

Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Brainstorm Cell Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – BCLI. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Brainstorm Cell Therapeutics stock price (NASDAQ: BCLI)

Use our graph to track the performance of BCLI stocks over time.

Brainstorm Cell Therapeutics shares at a glance

Information last updated 2023-01-25.
Latest market close$1.75
52-week range$1.09 - $4.70
50-day moving average $1.65
200-day moving average $2.84
Wall St. target price$7.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.64

Buy Brainstorm Cell Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Brainstorm Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Brainstorm Cell Therapeutics price performance over time

Historical closes compared with the close of $1.745 from 2023-01-30

1 week (2023-01-25) 20.34%
1 month (2022-12-30) 6.40%
3 months (2022-11-01) -50.85%
6 months (2022-08-01) -35.85%
1 year (2022-02-01) -45.81%
2 years (2021-02-01) -69.06%
3 years (2020-01-31) 4.07
5 years (2018-01-31) 3.48

Brainstorm Cell Therapeutics financials

Gross profit TTM $0
Return on assets TTM -68.31%
Return on equity TTM -193.43%
Profit margin 0%
Book value $0.04
Market capitalisation $53 million

TTM: trailing 12 months

Brainstorm Cell Therapeutics share dividends

We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.

Have Brainstorm Cell Therapeutics's shares ever split?

Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.

Brainstorm Cell Therapeutics share price volatility

Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $1.0854 up to $4.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is -0.398. This would suggest that Brainstorm Cell Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Brainstorm Cell Therapeutics has bucked the trend.

Brainstorm Cell Therapeutics overview

Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc.

Frequently asked questions

What percentage of Brainstorm Cell Therapeutics is owned by insiders or institutions?
Currently 22.696% of Brainstorm Cell Therapeutics shares are held by insiders and 10.617% by institutions.
How many people work for Brainstorm Cell Therapeutics?
Latest data suggests 43 work at Brainstorm Cell Therapeutics.
When does the fiscal year end for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's fiscal year ends in December.
Where is Brainstorm Cell Therapeutics based?
Brainstorm Cell Therapeutics's address is: 1325 Avenue of Americas, New York, NY, United States, 10019
What is Brainstorm Cell Therapeutics's ISIN number?
Brainstorm Cell Therapeutics's international securities identification number is: US10501E2019
What is Brainstorm Cell Therapeutics's CUSIP number?
Brainstorm Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 10501E102

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site